CN103922913A - Chalcone compounds and preparation method and application thereof. - Google Patents

Chalcone compounds and preparation method and application thereof. Download PDF

Info

Publication number
CN103922913A
CN103922913A CN201410138654.0A CN201410138654A CN103922913A CN 103922913 A CN103922913 A CN 103922913A CN 201410138654 A CN201410138654 A CN 201410138654A CN 103922913 A CN103922913 A CN 103922913A
Authority
CN
China
Prior art keywords
chalcone compounds
silica gel
preparation
compounds
chalcone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201410138654.0A
Other languages
Chinese (zh)
Other versions
CN103922913B (en
Inventor
胡秋芬
李银科
叶艳清
杜刚
杨海英
李萍艳
高雪梅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yunnan Minzu University
Original Assignee
Yunnan Minzu University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yunnan Minzu University filed Critical Yunnan Minzu University
Priority to CN201410138654.0A priority Critical patent/CN103922913B/en
Publication of CN103922913A publication Critical patent/CN103922913A/en
Application granted granted Critical
Publication of CN103922913B publication Critical patent/CN103922913B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/78—Separation; Purification; Stabilisation; Use of additives
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N35/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having two bonds to hetero atoms with at the most one bond to halogen, e.g. aldehyde radical
    • A01N35/04—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having two bonds to hetero atoms with at the most one bond to halogen, e.g. aldehyde radical containing aldehyde or keto groups, or thio analogues thereof, directly attached to an aromatic ring system, e.g. acetophenone; Derivatives thereof, e.g. acetals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
    • C07C49/83—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Abstract

The invention discloses chalcone compounds and a preparation method and application thereof. The chalcone compounds are separated from Desmodium renifolium and have a molecular formula of C20H20O5 and the structure of the chalcone compounds is shown in the specification. The preparation method of the chalcone compounds comprises the following steps: extracting extract from the whole Desmodium renifolium strain serving as a raw material and separating by column chromatography on silica gel and high pressure liquid chromatography. Particularly, the preparation method of the chalcone compounds comprises the following steps: pulverizing the whole Desmodium renifolium strain, carrying out ultrasonic extraction with methanol, mixing extractive solution, filtering, concentrating under reduced pressure to obtain an extract; loading the extract on the column by a silica gel dry method to carry out column chromatography on silica gel, gradiently eluting with chloroform-acetone solution having a volume ratio of (1:0) to (1:2), further separating and purifying 8:2 of eluate by high pressure liquid chromatography to obtain the chalcone compounds. The experimental results show that the chalcone compounds have good cell activity to tobacco mosaic virus (TMV). The chalcone compounds disclosed by the invention are simple in structure, can be synthesized artificially, have good activity and can be used as anti-TMV lead compounds.

Description

A kind of Chalcone Compounds and its preparation method and application
Technical field
The invention belongs to vegetable chemistry technical field, be specifically related to a kind of Chalcone Compounds extracting and preparation method thereof and application from renal lobe beggarweed.
Background technology
Renal lobe beggarweed is pulse family undershrub, is mainly distributed in Yunnan, Shaanxi, Sichuan, Hubei, Hunan, Jiangxi, Fujian, Zhejiang, Jiangsu; In Korea, also there is distribution in Japan.Renal lobe beggarweed is China's conventional Chinese medicinal materials among the people, and root and over-ground part complete stool are medicinal, have the effects such as expelling wind and activating blood circulation, diuresis, desinsection.Study and show both at home and abroad, renal lobe beggarweed main active ingredient is flavonoid compound, comprises flavones, isoflavones, cinnamophenone etc.Cinnamophenone refers to the compound that contains 1,3-diphenylprop ketenes structure in molecule.They are distributed in root, leaf and the skin of multiple medicinal plant in a large number.Because its molecular structure has larger flexibility, can with multiple receptors bind, present biological activity widely, as antitumor, suppress and remove oxyradical, antibacterial, parasiticide, antiviral, antiulcer agent etc.Existing studies confirm that simultaneously, its pharmacological action and chemical structure are closely related, can further research and develop more Chalcone Compounds, therefrom find effective lead compound and active group.The present invention separates and has obtained a kind of new Chalcone Compounds with activity of resisting tobacco mosaic virus from renal lobe beggarweed, and this compound it is not yet seen relevant report.
Summary of the invention
The first object of the present invention is to provide a kind of Chalcone Compounds; The second object is to provide the preparation method of described Chalcone Compounds; The 3rd object is to provide described Chalcone Compounds in the application of preparing in resisting tobacco mosaic disease medicine.
The first object of the present invention is achieved in that described compound is to separate and obtain from renal lobe beggarweed, and its molecular formula is C 20h 20o 5, there is following structure:
This compound is yellow jelly, called after beggarweed phenyl styryl ketone A.Chemical name is: 2-((1 s, 2 r)-4,5-dihydroxy-2-(prop-1-en-2-yl)-2,3-dihydro-1H-inden-1-yl)-1-(2,4-dihydroxyphenyl) ethanone.
The second object of the present invention is achieved in that the preparation method of described Chalcone Compounds is taking renal lobe beggarweed as raw material, through medicinal extract extraction, silica gel column chromatography, high pressure liquid chromatography separating step, is specially:
A, medicinal extract extract: get renal lobe beggarweed sample complete stool, be crushed to 2 ~ 40 orders, and by 90 ~ 99% methyl alcohol supersound extraction 3 ~ 5 times, each 30 ~ 60 min, united extraction liquid, filtration, concentrating under reduced pressure becomes medicinal extract;
B, silica gel column chromatography: medicinal extract carries out silica gel column chromatography with 160 ~ 200 order silica gel dry column-packings of 2 ~ 3 times of amounts of weight ratio; Chloroform-acetone solution taking volume proportion as 1:0 ~ 1:2 is carried out gradient elution, merges identical part, collects each several part elutriant concentrated;
C, high pressure liquid chromatography separate: the 8:2 part of B step elutriant further obtains described Chalcone Compounds with high pressure liquid chromatography separation and purification.
The structure of the Chalcone Compounds of preparing with aforesaid method is to measure out by the following method:
The compounds of this invention is yellow jelly; Specific rotatory power for-2.86 (solvent is methyl alcohol, c0.20) UV spectrum (solvent is methyl alcohol), λ max(log ε) 210 (4.62), 225 (4.46), 290 (4.16); Infrared spectra (pressing potassium bromide troche) ν max3392,3142,3085,2954,2876,1643,1602,1565,1468,1347,1196,1062,871 cm -1; High resolution mass spectrum (HRESIMS) provides quasi-molecular ion peak m/z[339.1238 M-H] -(calculated value 339.1232).In conjunction with 1h and 13c NMR spectrum provides a molecular formula C 20h 20o 5, degree of unsaturation is 11.From 1h and 13cNMR spectrum (attribution data is in Table-1) signal can find out in compound have one 1,2,3, the quaternary phenyl ring of 4-and one 1 ', 2 ', 3 '-trisubstituted phenyl ring, has four hydroxyls replacements on phenyl ring; In addition, in compound, also have the two keys of one group of end group, two methylene radical, two methynes, a methyl and a ketone carbonyl signal.These data show that this compound is three ring phenyl styryl ketone structures, common phenyl styryl ketone phenyl ring 2-position replace isopentene group on 2 ' ' position and β-carbon has formed five yuan of carbocyclic rings.H 3-5 ' ' ( δ h1.69) and H 2-4 ' ' ( δ h4.86) with C-2 ' ' and C-3 ' '; H-2 ' ' ( δ h3.19) and C-1, C-1 ' ', C-2, C-4 ' ', C-5 ' ', C- αwith c-β; H 2- α( δ h2.97 and 2.92) with C-1 ', C- β, C-1, C=O, and C-2 ' '; H- β( δ h3.84) and C-1, C-1 ' ', C- α, C-2, and C-2 ' '; H-1 ' ' ( δ h2.94) and C-1, C-2, C-2 ' ', C- β, and between C-3 ' ', there is HMBC be correlated with (Fig. 1); In addition H, 2- α/ H- β/ H-2 ' '/H 2-1 ' ' between exist 1h- 1h COSY, these data also confirm this phenyl styryl ketone structure.Its Relative configuration is determined by coupling constant and the known compound contrast of ROESY Correlated Spectroscopy, specific rotation and hydrogen spectrum.So far the structure of this compound is determined.
table-1. compound 1 h NMR and 13 c NMR data (CD 3 ) 2 cO)
The 3rd object of the present invention is achieved in that by described Chalcone Compounds and is applied to the preparation in tobacco mosaic disease medicine.
The compounds of this invention is separated first, has determined for Chalcone Compounds, and characterized its concrete structure by nucleus magnetic resonance and measuring method of mass spectrum.Through the experiment to resisting tobacco mosaic virus, its relative inhibition reaches 52.1%, has good activity of resisting tobacco mosaic virus, than the relative inhibition of positive reference substance Nanning mycin (31.2%) height.Above result has disclosed compound of the present invention has good application prospect preparing in resisting tobacco mosaic virus medicine.The compounds of this invention activity simple in structure is good, can be used as the guiding compound of resisting tobacco mosaic virus medicine.
Brief description of the drawings
Fig. 1 is the carbon-13 nmr spectra of compound;
Fig. 2 is the proton nmr spectra of compound;
The HSQC Correlated Spectroscopy of Fig. 3 compound;
The HMBC Correlated Spectroscopy of Fig. 4 compound;
Fig. 5 compound 1h- 1h COSY Correlated Spectroscopy;
The ROESY Correlated Spectroscopy of Fig. 6 compound;
Fig. 7 is the main of compound 1h- 1h COSY is relevant with HMBC.
Embodiment
Below in conjunction with embodiment and accompanying drawing, the present invention is further illustrated, but never in any form the present invention is limited, and any conversion or the improvement done based on training centre of the present invention, all fall into protection scope of the present invention.
Except as otherwise noted, the percentage ratio adopting in the present invention is mass percent.
Chalcone Compounds C of the present invention 20h 20o 5preparation method comprise medicinal extract extraction, silica gel column chromatography, high pressure liquid chromatography separating step, specifically comprise:
A, medicinal extract extract: get renal lobe beggarweed sample, be crushed to 20 ~ 40 orders, and by 90 ~ 99% methyl alcohol supersound extraction 3 ~ 5 times, each 30 ~ 60 min, united extraction liquid, filtration, concentrating under reduced pressure becomes medicinal extract;
B, silica gel column chromatography: medicinal extract carries out silica gel column chromatography with 160 ~ 200 order silica gel dry column-packings of 2 ~ 3 times of amounts of weight ratio; Chloroform-acetone solution taking volume proportion as 1:0 ~ 1:2 is carried out gradient elution, merges identical part, collects each several part elutriant concentrated;
C, high pressure liquid chromatography separate: the 8:2 part of B step elutriant further obtains described Chalcone Compounds with high pressure liquid chromatography separation and purification.
The solvent methanol concentration of described A step is 95%.
The medicinal extract of described B step is before silica gel column chromatography rough segmentation, with 80 ~ 100 order silica gel mixed samples by 0.8 ~ 1.2 times of weight ratio after the pure dissolve with methanol of 1.5 ~ 3 times of amounts of weight ratio.
The chloroform-acetone solution volume proportion of described B step is 1:0,20:1,9:1,8:2,7:3,6:4,1:1,1:2.
The separation and purification of described C step mesohigh liquid chromatography is to adopt 21.2 mm × 250 mm, 5 μthe C of m 18chromatographic column, flow velocity is 20 mL/min, the methyl alcohol that moving phase is 58%, it is 390 nm that UV-detector detects wavelength, each sample introduction 200 μl, the chromatographic peak of collection 21.4 min, repeatedly cumulative rear evaporate to dryness.
Material after the separation and purification of described C step mesohigh liquid phase chromatography is used pure dissolve with methanol again, then taking pure methyl alcohol as moving phase, with gel filtration chromatography separation, with further separation and purification.
Chalcone Compounds of the present invention is in the application of preparing in resisting tobacco mosaic virus medicine.
Raw materials used area and the kind of not being subject to of the present invention limits, and all can realize the present invention, and to derive from the renal lobe beggarweed sample in Yunnan, the present invention will be further described below:
embodiment 1
Renal lobe beggarweed sample source is in In Xishuangbanna of Yunnan.Renal lobe beggarweed is sampled to 2.2 kg and be crushed to 30 orders, 30min is extracted in supersound extraction 3 times of the methyl alcohol with 95% at every turn, and extracting solution merges, and filters, and concentrating under reduced pressure becomes medicinal extract, obtains medicinal extract 88.5 g.The thick silica gel mixed sample of 100 order with 120 g after the pure dissolve with methanol of 2.5 times of amounts of weight ratio for medicinal extract, the 160 order silica gel dress posts of 1.5 kg carry out silica gel column chromatography, with volume proportion be 1:0, 20:1, 9:1, 8:2, 7:3, 6:4, 1:1, chloroform-acetone gradient elution of 1:2, TLC monitoring merges identical part, obtain 8 parts, chloroform-acetone wash-out part that wherein volume proportion is 8:2 separates with prompt logical sequence 1,100 half preparative high-performance liquid chromatographics of peace, methyl alcohol taking 58% is moving phase, Zorbax SB-C18 (21.2 × 250 mm, 5 μ m) preparative column are stationary phase, flow velocity is 20 ml/min, it is 290 nm that UV-detector detects wavelength, each sample introduction 200 μ L, collect the chromatographic peak of 21.4 min, repeatedly cumulative rear evaporate to dryness, products therefrom is used pure dissolve with methanol again, then taking pure methyl alcohol as moving phase, with the separation of Sephadex LH-20 gel filtration chromatography, obtains this new compound.
embodiment 2
Renal lobe beggarweed sample source, in Yunnan Dehong, is crushed to 40 orders by renal lobe beggarweed sampling 3.5kg, and 45 min are extracted in supersound extraction 5 times of the methyl alcohol with 90% at every turn, and extracting solution merges, and filters, and concentrating under reduced pressure becomes medicinal extract, obtains medicinal extract 158 g.The thick silica gel mixed sample of 80 order with 300 g after the pure dissolve with methanol of 2.0 times of amounts of weight ratio for medicinal extract, the 200 order silica gel dress posts of 1.5 kg carry out silica gel column chromatography, with volume proportion be 1:0, 20:1, 9:1, 8:2, 7:3, 6:4, 1:1, chloroform-acetone gradient elution of 1:2, TLC monitoring merges identical part, obtain 8 parts, chloroform-acetone wash-out part that wherein volume proportion is 8:2 separates with prompt logical sequence 1,100 half preparative high-performance liquid chromatographics of peace, methyl alcohol taking 58% is moving phase, Zorbax SB-C18 (21.2 × 250 mm, 5 μ m) preparative column are stationary phase, flow velocity is 20 ml/min, it is 290 nm that UV-detector detects wavelength, each sample introduction 200 μ L, collect the chromatographic peak of 21.4 min, repeatedly cumulative rear evaporate to dryness, products therefrom is used pure dissolve with methanol again, then taking pure methyl alcohol as moving phase, with the separation of Sephadex LH-20 gel filtration chromatography, obtains this new compound.
embodiment 3
Renal lobe beggarweed sample source, in Honghe, Yunnan, samples 5 kg by renal lobe beggarweed and is crushed to 60 orders, and 60 min are extracted in supersound extraction 3 times of the methyl alcohol with 99% at every turn, and extracting solution merges, and filters, and concentrating under reduced pressure becomes medicinal extract, obtains medicinal extract 350 g.The thick silica gel mixed sample of 90 order with 500 g after the pure dissolve with methanol of 1.6 times of amounts of weight ratio for medicinal extract, the 180 order silica gel dress posts of 1.8 kg carry out silica gel column chromatography, with volume proportion be 1:0, 20:1, 9:1, 8:2, 7:3, 6:4, 1:1, chloroform-acetone gradient elution of 1:2, TLC monitoring merges identical part, obtain 8 parts, chloroform-acetone wash-out part that wherein volume proportion is 8:2 separates with prompt logical sequence 1,100 half preparative high-performance liquid chromatographics of peace, methyl alcohol taking 58% is moving phase, Zorbax SB-C18 (21.2 × 250 mm, 5 μ m) preparative column are stationary phase, flow velocity is 20 ml/min, it is 290 nm that UV-detector detects wavelength, each sample introduction 200 μ L, collect the chromatographic peak of 21.4 min, repeatedly cumulative rear evaporate to dryness, products therefrom is used pure dissolve with methanol again, then taking pure methyl alcohol as moving phase, with the separation of Sephadex LH-20 gel filtration chromatography, obtains this new compound.
embodiment 4
Getting compound prepared by embodiment 1, is yellow jelly.
Measuring method is: with nucleus magnetic resonance, in conjunction with other spectroscopic technique qualification structure.
The compounds of this invention is yellow jelly; Specific rotatory power for-2.86 ( c0.20, MeOH) UV spectrum (solvent is methyl alcohol), λ max(log ε) 210 (4.62), 225 (4.46), 290 (4.16); Infrared spectra (pressing potassium bromide troche) ν max3392,3142,3085,2954,2876,1643,1602,1565,1468,1347,1196,1062,871 cm -1; High resolution mass spectrum (HRESIMS) provides quasi-molecular ion peak m/z[339.1238 M-H] -(calculated value 339.1232).In conjunction with 1h and 13c NMR spectrum provides a molecular formula C 20h 20o 5, degree of unsaturation is 11.From 1h and 13cNMR spectrum (attribution data is in Table-1) signal can find out in compound have one 1,2,3, the quaternary phenyl ring of 4-and one 1 ', 2 ', 3 '-trisubstituted phenyl ring, has four hydroxyls replacements on phenyl ring; In addition, in compound, also have the two keys of one group of end group, two methylene radical, two methynes, a methyl and a ketone carbonyl signal.These data show that compound is three ring phenyl styryl ketone structures, common phenyl styryl ketone phenyl ring 2-position replace isopentene group on 2 ' ' position and β-carbon has formed five yuan of carbocyclic rings.H 3-5 ' ' ( δ h1.69) and H 2-4 ' ' ( δ h4.86) with C-2 ' ' and C-3 ' '; H-2 ' ' ( δ h3.19) and C-1, C-1 ' ', C-2, C-4 ' ', C-5 ' ', C- αwith c-β; H 2- α( δ h2.97 and 2.92) with C-1 ', C- β, C-1, C=O, and C-2 ' '; H- β( δ h3.84) and C-1, C-1 ' ', C- α, C-2, and C-2 ' '; H-1 ' ' ( δ h2.94) and C-1, C-2, C-2 ' ', C- β, and between C-3 ' ', there is HMBC be correlated with (Fig. 1); In addition H, 2- α/ H- β/ H-2 ' '/H 2-1 ' ' between exist 1h- 1h COSY, these data also confirm this phenyl styryl ketone structure.Its Relative configuration is determined by coupling constant and the known compound contrast of ROESY Correlated Spectroscopy, specific rotation and hydrogen spectrum.So far the structure of this compound is determined.
embodiment 5
Getting compound prepared by embodiment 2, is yellow jelly.Measuring method is identical with embodiment 4, confirms that compound prepared by embodiment 2 is described Chalcone Compounds---beggarweed phenyl styryl ketone A.
embodiment 6
Getting compound prepared by embodiment 3, is yellow jelly.Measuring method is identical with embodiment 4, confirms that compound prepared by embodiment 3 is described Chalcone Compounds---beggarweed phenyl styryl ketone A.
embodiment 7
Arbitrary Chalcone Compounds of getting embodiment 1 ~ 3 preparation carries out activity of resisting tobacco mosaic virus test, and test situation is as follows:
Adopt half leaf method, in the time that the mass concentration of medicament is 50 mg/L, the compounds of this invention is carried out to activity of resisting tobacco mosaic virus mensuration.5～6 age flue-cured tobacco plant on, choose be applicable to test blade (leaf is capable normal, anosis without worm), first blade is evenly sprinkled to fine emery powder, with writing brush by tobacco mosaic virus (TMV) source (3.0 × 10 for subsequent use -3) be evenly put on the blade sprinkled with silicon carbide, after the blade of all middle choosings connects poison and finishes, be placed on immediately and in the culture dish that fills liquid, process 20 min, take out, wipe the globule and liquid on blade, two and half leaves are restored and are emitted in the glass jar that is covered with toilet paper moisturizing, and cover glass cover, temperature control (23 ± 2) DEG C, be placed on greenhouse natural light irradiation, 2～3 d are visible withered spot. each processing establish second half leaf for contrast, be provided with in addition 1 group be commodity Ningnanmycin processing as a comparison, press formula calculate relative inhibition.
XI％=(CK-T)／CK×100％
X: relative inhibition (%), CK: be soaked in half sheet in clear water and connect the withered spot number (individual) of malicious leaf, T is soaked in half sheet in liquid and connects the withered spot number (individual) of malicious leaf.
The relative inhibition of bright compound of result is 52.1%, far above the relative inhibition 31.2% of contrast Ningnanmycin, illustrates that compound has good activity of resisting tobacco mosaic virus.

Claims (8)

1. a Chalcone Compounds, is characterized in that described Chalcone Compounds is to separate and obtain from renal lobe beggarweed, and its molecular formula is C 20h 20o 5, there is following structure:
。
2. a preparation method for Chalcone Compounds claimed in claim 1, is characterized in that, taking renal lobe beggarweed complete stool as raw material, through medicinal extract extraction, silica gel column chromatography, high pressure liquid chromatography separating step, being specially:
A, medicinal extract extract: get renal lobe beggarweed sample, be crushed to 20 ~ 40 orders, and by 90 ~ 99% methyl alcohol supersound extraction 3 ~ 5 times, each 30 ~ 60 min, united extraction liquid, filtration, concentrating under reduced pressure becomes medicinal extract;
B, silica gel column chromatography: medicinal extract carries out silica gel column chromatography with 160 ~ 200 order silica gel dry column-packings of 2 ~ 3 times of amounts of weight ratio; Chloroform-acetone solution taking volume proportion as 1:0 ~ 1:2 is carried out gradient elution, merges identical part, collects each several part elutriant concentrated;
C, high pressure liquid chromatography separate: the 8:2 part of B step elutriant further obtains described Chalcone Compounds with high pressure liquid chromatography separation and purification.
3. the preparation method of Chalcone Compounds as claimed in claim 2, is characterized in that in described A step, methanol concentration is 95%.
4. the preparation method of Chalcone Compounds as claimed in claim 2, is characterized in that in described B step that medicinal extract is before silica gel column chromatography rough segmentation, with 80 ~ 100 order silica gel mixed samples by 0.8 ~ 1.2 times of weight ratio after the pure dissolve with methanol of 1.5 ~ 3 times of amounts of weight ratio.
5. the preparation method of Chalcone Compounds as claimed in claim 2, is characterized in that in described B step, chloroform-acetone solution volume proportion is 1:0,20:1,9:1,8:2,7:3,6:4,1:1,1:2.
6. the preparation method of Chalcone Compounds as claimed in claim 2, is characterized in that: described C step mesohigh liquid chromatography separation and purification is to adopt 21.2 mm × 250 mm, 5 μthe C of m 18chromatographic column, flow velocity is 20 mL/min, the methyl alcohol that moving phase is 58%, it is 290 nm that UV-detector detects wavelength, each sample introduction 200 μl, the chromatographic peak of collection 21.4 min, repeatedly cumulative rear evaporate to dryness.
7. the preparation method of Chalcone Compounds as claimed in claim 2, it is characterized in that the material after the separation and purification of described C step mesohigh liquid chromatography uses pure dissolve with methanol again, again taking pure methyl alcohol as moving phase, with gel filtration chromatography separation, with further separation and purification.
8. a Chalcone Compounds claimed in claim 1 is in the application of preparing in resisting tobacco mosaic virus medicine.
CN201410138654.0A 2014-04-09 2014-04-09 A kind of Chalcone Compounds and its preparation method and application Expired - Fee Related CN103922913B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410138654.0A CN103922913B (en) 2014-04-09 2014-04-09 A kind of Chalcone Compounds and its preparation method and application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410138654.0A CN103922913B (en) 2014-04-09 2014-04-09 A kind of Chalcone Compounds and its preparation method and application

Publications (2)

Publication Number Publication Date
CN103922913A true CN103922913A (en) 2014-07-16
CN103922913B CN103922913B (en) 2015-08-19

Family

ID=51141342

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201410138654.0A Expired - Fee Related CN103922913B (en) 2014-04-09 2014-04-09 A kind of Chalcone Compounds and its preparation method and application

Country Status (1)

Country Link
CN (1) CN103922913B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104292202A (en) * 2014-09-15 2015-01-21 云南民族大学 Flavonoid compound as well as preparation method and application of flavonoid compound

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11236328A (en) * 1997-12-16 1999-08-31 Mitsui Chem Inc Cosmetic comprising hydrochalcone derivative and/or chalcone derivative as active ingredient

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11236328A (en) * 1997-12-16 1999-08-31 Mitsui Chem Inc Cosmetic comprising hydrochalcone derivative and/or chalcone derivative as active ingredient

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YAN-PING LI, ET AL.,: "Five new prenylated chalcones from Desmodium renifolium", 《FITOTERAPIA》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104292202A (en) * 2014-09-15 2015-01-21 云南民族大学 Flavonoid compound as well as preparation method and application of flavonoid compound
CN104292202B (en) * 2014-09-15 2015-12-09 云南民族大学 A kind of flavonoid compound and its preparation method and application

Also Published As

Publication number Publication date
CN103922913B (en) 2015-08-19

Similar Documents

Publication Publication Date Title
CN105399656B (en) A kind of iso-indoles alkaloid compound and preparation method and application
CN103304530B (en) Coumarin compound and preparation method and application thereof
CN103524472B (en) Phenolic compound, and preparation method and application thereof
CN103554077B (en) Chromone compound as well as preparation method and application thereof
CN102304114B (en) Flavanone compound and application thereof
CN105348192A (en) Antiviral-activity isoquinoline alkaloid compound in Cassia alata L. and preparation method of antiviral-activity isoquinoline alkaloid compound
CN104497000A (en) Tobacco mosaic virus-resistant plant flavonoids compound as well as preparation method and applications thereof
CN106146383B (en) A kind of iso-indoles alkaloid compound, preparation method and application in tobacco
CN103896755B (en) A kind of chalcone compounds preparation method
CN104610219B (en) A kind of xanthones compound with oxidation isopentene group and its preparation method and application
CN104292202B (en) A kind of flavonoid compound and its preparation method and application
CN104292203A (en) Isocoumarin compound and preparation method and application thereof
CN104387361B (en) A kind of Isocoumarin compounds and its production and use
CN109535169A (en) A kind of chromone derivative and its preparation method and application
CN110357894A (en) A kind of tricyclic alkaloid compound and the preparation method and application thereof
CN103922913B (en) A kind of Chalcone Compounds and its preparation method and application
CN105017198A (en) Preparation of isobutylene flavonoids in sun-cured tobacco and application of isobutylene flavonoids for resisting tobacco mosaic virus
CN102772501A (en) Rheum emodi Wall. extract and its preparing method
CN113200911B (en) Quinoline alkaloid compound and preparation method and application thereof
CN103554071B (en) Amidpulver compound and preparation method and application thereof
CN104650053B (en) Flavonoids compound, as well as preparation method and applications thereof
CN103012425B (en) Benzofuran compound, and preparation method and application thereof
CN104370874B (en) A kind of parallel heptatomic ring biphenyl compound and its preparation method and application
CN109438464A (en) A kind of chromone derivative and its preparation method and application extracted from short leaf Cassia
CN109438406A (en) A kind of chromone derivative and its preparation method and application extracted from handle gland senna

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150819

Termination date: 20160409